Could you write me a little essay explaining what
(if anything) batch validation of a set of reagents achieves in a hospital
laboratory that the internal and external quality control samples doesn't
Certainly. Here's a concise essay
that you could adapt for a laboratory quality manual, training document, or
discussion paper.
What Does Batch Validation of
Reagents Achieve Beyond Internal and External Quality Control?
Clinical laboratories rely on
several layers of quality assurance to ensure that test results are accurate,
reliable and fit for clinical use. Internal quality control (IQC), external
quality assessment (EQA), and reagent batch validation all contribute to this
objective, but they serve different purposes. While IQC and EQA monitor the
ongoing performance of an assay, batch validation specifically assesses the
impact of introducing a new lot of reagent before patient results are reported.
Internal quality control is
designed to detect analytical errors on a day-to-day basis. Control materials
with known target values are analysed alongside patient samples, allowing
laboratories to identify random or systematic shifts in assay performance.
External quality assessment provides an independent comparison with other
laboratories and methods, helping to identify bias or calibration issues that
may not be visible through internal monitoring alone.
However, neither IQC nor EQA can
fully guarantee that a new reagent batch will perform identically to the
previous one. Quality control materials are often artificial matrices that may
not behave in exactly the same way as patient specimens. Furthermore, IQC
normally assesses only a small number of concentration levels, whereas patient
samples can span a much wider analytical range. EQA samples are generally
infrequent, perhaps monthly or quarterly, and therefore may not detect problems
immediately after a reagent change.
Reagent batch validation
addresses this specific risk. Before a new batch is released for routine use,
laboratories compare its performance against the current validated batch using
a selection of patient samples. This process determines whether the new lot
produces clinically equivalent results across the measurement range and whether
any significant bias has been introduced. Even when IQC results remain within
acceptable limits, a reagent lot can occasionally produce a small systematic
shift that is clinically important, particularly for assays used in diagnosis,
therapeutic drug monitoring, tumour markers, cardiac markers, or endocrine
testing.
Another important advantage of
batch validation is the ability to detect lot-to-lot variation before it
affects patient care. Manufacturers work to ensure consistency between
production batches, but minor differences in raw materials, manufacturing conditions,
or calibration assignment can occur. By evaluating real patient specimens, the
laboratory verifies that these variations do not alter clinical interpretation.
Batch validation also provides
documented evidence that the laboratory has exercised due diligence when
introducing a new reagent lot. This is an important element of accreditation
requirements such as ISO 15189 and demonstrates that the laboratory has assessed
the risk of reagent changes rather than relying solely on manufacturer claims
or routine QC performance.
In summary, internal quality
control answers the question, "Is the assay performing acceptably
today?" External quality assessment answers, "Are our results
comparable with those of other laboratories?" Reagent batch validation
answers a different but equally important question: "Will this new reagent
lot produce patient results that are equivalent to those generated by the
previous validated lot?" Because these questions are distinct, batch
validation remains an essential component of a comprehensive laboratory quality
system rather than a duplication of IQC or EQA processes.
One point often made by
laboratories looking to streamline processes is that for very stable, mature
assays with an excellent history of lot-to-lot consistency, reagent batch
validation may occasionally identify few problems over many years. Nevertheless,
its value lies in providing assurance against the rare but potentially
significant lot change that neither routine IQC nor periodic EQA would
necessarily detect before patient results are affected.
That's excellent. Thank you... But surely if there
was a batch-to-batch difference this would show up in the QC results?
That's an excellent question, and
it's exactly the argument many laboratories use when considering whether
extensive lot-to-lot validation is worth the effort.
The honest answer is: often
yes, a significant batch-to-batch difference would be detected by QC,
but not always.
The key issue is that QC
materials are being used as a surrogate for patient samples, and
surrogates are rarely perfect.
For example:
- A reagent lot introduces a 5% positive bias.
- Your QC target is 100 units with acceptable limits
of ±10 units.
- The QC result shifts from 100 to 105.
The QC remains comfortably
"in control" despite the new lot causing a real change in patient
results.
From a laboratory quality
perspective, the assay is performing acceptably. From a clinical perspective,
however, a 5% change might be important for certain tests such as troponin,
PSA, HbA1c, therapeutic drugs, TSH, or some tumour markers.
In other words, QC is primarily
designed to detect when an assay becomes unacceptable, whereas lot
validation is designed to detect whether a new lot is equivalent to the
previous one.
Another issue is what is often
called matrix effects. QC materials are manufactured products. Even very
high-quality controls are not identical to human serum, plasma, urine, or whole
blood. Occasionally a reagent change may affect patient samples and QC material
differently. In these circumstances the QC can appear perfectly satisfactory
while patient results shift.
A simple analogy would be
weighing scales. If you check a new scale with a 10 kg calibration weight and
it reads correctly, you have shown it can measure that particular weight. You
have not necessarily demonstrated that it will give identical readings for
every object you subsequently weigh.
There's also a practical
accreditation aspect. If a laboratory relies solely on QC, it is effectively
saying:
"We know the assay still
produces acceptable results."
Lot validation asks a slightly
different question:
"Have patient results
changed compared with yesterday?"
For many tests, those questions
lead to the same answer. For a few important assays, they occasionally do not.
That said, there is a perfectly
reasonable counterargument. Modern instrumentation, manufacturer QC procedures,
highly stable reagent production, third-party controls, moving averages,
patient medians, and frequent EQA all reduce the risk considerably. Some
laboratories have accumulated years of data showing negligible lot-to-lot
variation and therefore perform only limited validation on certain low-risk
assays.
So if I were writing this for a
scientific audience, I'd probably conclude:
Internal and external quality
control will detect many, and perhaps most, clinically significant reagent lot
changes. The principal justification for separate lot validation is not that QC
is ineffective, but that QC demonstrates ongoing assay acceptability, whereas
lot validation demonstrates comparability of patient results before and after a
reagent change. The value of lot validation therefore depends on the assay's
susceptibility to lot-to-lot variation and the clinical consequences of even
small analytical biases.
That's a slightly less dogmatic
position than some accreditation guidance implies, and I think it's closer to
the reality of modern laboratory practice.
So what does the batch validation achieve that
isn't already monitored by the delta checks on the moving average?
You've now reached the point
where many laboratory scientists start asking whether reagent lot validation is
primarily a scientific necessity or an accreditation requirement.
If you have:
- Internal QC
- External QA
- Delta checks
- Moving averages (or patient-based real-time QC)
- Review of patient medians
- Clinical review of unexpected result distributions
then the unique contribution of
reagent lot validation becomes increasingly narrow.
The key difference is timing.
A moving average or patient
median process tells you:
"A shift has occurred."
Lot validation asks:
"Has a shift occurred before
I release any patient results?"
For example, if a new reagent lot
causes sodium results to increase by 1 mmol/L, a moving average system will
probably detect that fairly quickly. However, it may require dozens or hundreds
of patient results before the shift becomes statistically significant. By that
point, some patient reports have already been issued.
Lot validation is intended to
detect the shift prospectively, before the first clinical result is
released.
The counterargument, of course,
is entirely reasonable:
If my moving average system is
sensitive enough to detect clinically important shifts quickly, and the risk
associated with releasing a small number of results before detection is
acceptable, what extra benefit am I actually gaining from extensive lot validation?
For many routine chemistry
assays, the answer may genuinely be "very little".
In fact, patient-based quality
control methods are often statistically more powerful than traditional QC
because they interrogate hundreds or thousands of genuine patient samples
rather than a handful of artificial control materials.
One could argue that:
- IQC monitors assay stability.
- EQA monitors comparability with peers.
- Moving averages monitor actual patient performance.
- Delta checks monitor individual patient
consistency.
Collectively, these systems may
be more sensitive to clinically relevant change than testing 10 or 20 stored
samples during a lot-to-lot comparison.
The strongest remaining
justification for lot validation is therefore not necessarily superior
detection capability, but rather preventive assurance. It provides
evidence that the laboratory consciously assessed the risk of a reagent change
before patient testing commenced.
If I were writing a balanced
scientific critique, I might say:
The incremental benefit of
reagent lot validation diminishes as laboratories adopt sophisticated
patient-based quality assurance tools such as moving averages and delta checks.
These systems are capable of detecting clinically relevant shifts in assay performance
using real patient data and may identify changes that are more representative
of routine clinical practice than conventional lot validation studies. The
principal advantage of lot validation is that it provides a prospective
assessment before patient results are released, whereas patient-based
monitoring systems generally detect changes only after testing has begun.
So the really important question
becomes:
"How many incorrect
patient results am I willing to release before my monitoring system detects a
problem?"
Lot validation aims for zero.
Moving-average and delta-check
systems may detect the problem after 10, 100, or 1,000 results, depending on
the assay and the alert thresholds.
Whether that difference justifies
the cost and workload of full reagent lot validation is, in my view, a
legitimate topic for debate rather than a settled scientific question.
That's excellent - thank you...
You're very welcome, David.
To be honest, I think you've put
your finger on one of the more interesting tensions in modern laboratory
quality management.
Historically, reagent lot
validation evolved when laboratories had relatively crude QC systems,
infrequent EQA, and little or no patient-based quality monitoring. In that
environment, validating a new lot against the old lot made a great deal of
sense because it was often the only practical way to detect a subtle shift
before patient reporting began.
Today, many laboratories have:
- Multiple levels of IQC
- Frequent EQA participation
- Delta checks
- Moving averages
- Patient medians and percentile monitoring
- Autoverification rules
- Highly stable reagent manufacture
- Sophisticated middleware analytics
Once all of those are in place,
it is reasonable to ask whether lot validation is providing unique clinical
protection or merely another layer of assurance.
The strongest defence of lot
validation is that it is prospective: it aims to prevent a problem
before any patient result is released.
The strongest criticism is that
it often uses a relatively small number of samples and may be statistically
less powerful than modern patient-based QC tools that continuously monitor
hundreds or thousands of real patient results.
A quality manager will often
frame the question as:
"Can we demonstrate that the
risk of a clinically significant lot change escaping our existing monitoring
systems is acceptably low?"
If the answer is yes, then one
can argue for a more risk-based and proportionate approach to lot validation.
In fact, many of the papers
published over the last decade on patient-based real-time quality control are,
implicitly, asking exactly the same question that you're asking:
If we are continuously monitoring
real patient results with highly sensitive statistical techniques, how much
additional protection is provided by traditional QC and lot-verification
processes?
There isn't complete consensus
yet, which is why most accreditation bodies still expect lot verification. But
scientifically, your challenge is entirely valid.
My suspicion is that over the
next 10-20 years we'll see more laboratories moving towards a risk-based model
where the extent of lot validation depends on:
- the assay,
- the clinical consequences of bias,
- the historical lot-to-lot performance,
- and the strength of patient-based monitoring
systems already in place.
For a high-sensitivity troponin
assay, you'd probably still want rigorous lot verification.
For a well-behaved routine
chemistry assay with stable moving averages and years of negligible lot shifts,
the argument for extensive validation becomes much harder to make.
In short, QC asks, "Is the
method under control?", moving averages ask, "Have patient results
shifted?", and lot validation asks, "Can we show they haven't shifted
before we start reporting?" Whether that final question justifies a
separate process for every assay is, in my view, a perfectly legitimate
scientific debate.
I then asked it to make a little picture of our
conversation and it came up with the picture above…
And its final comment is exactly what I thought
all along…
I hope the caricature captures
the spirit of the conversation: a laboratory scientist relentlessly (and quite
reasonably) dismantling every quality-management argument put before him, while
a cheerful AI desperately clings to its little "But what about batch
validation?" placard.
My favourite detail is that the
discussion somehow progressed from IQC and reagent lots to the much deeper
question:
"Are we doing this because
it's scientifically necessary, or because someone wrote it into an
accreditation document twenty years ago?"
...which is exactly the sort of
question that keeps curious minds, laboratory scientists, and over-enthusiastic
AIs happily occupied over a cup of coffee. 😄
